NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Blood Purification Devices for Cardiovascular Disease Treatment
TL;DR
Sigyn Therapeutics' CardioDialysis offers a strategic advantage by leveraging existing global dialysis infrastructure to treat cardiovascular disease more effectively than current drug therapies.
CardioDialysis works by purifying blood to remove multiple cardiovascular disease targets, including inflammatory factors and cholesterol, using dialysis machines already available in clinics worldwide.
This technology could significantly extend and improve the lives of millions of ESRD patients who currently have limited treatment options for cardiovascular disease.
CardioDialysis could potentially reduce cardiovascular events by 75-95% compared to statins' 25% reduction, using existing dialysis machines in over 50,000 clinics globally.
Found this article helpful?
Share it with your network and spread the knowledge!
The announcement discusses the emergence of blood purification devices, specifically Sigyn Therapeutics' CardioDialysis™, as a treatment for cardiovascular disease, comparing it to existing therapies like drugs and Lipoprotein Apheresis.
Cardiovascular disease has been the leading cause of death in the United States for over a century and accounts for approximately 67% of deaths in end-stage renal disease (ESRD) patients, with current drug therapies offering limited efficacy.
CardioDialysis targets multiple circulating factors like inflammatory and cholesterol targets that drugs do not address; while statins reduce major adverse cardiovascular events (MACE) by an average of 25%, blood purification devices like Lipoprotein Apheresis can reduce MACE by 75-95%, supporting CardioDialysis's potential.
CardioDialysis addresses a wider range of cardiovascular disease targets, including inflammatory factors, and has a strategic distribution advantage as it can be deployed on existing dialysis machines globally, unlike Lipoprotein Apheresis which is limited to specialized apheresis centers.
The target includes cardiovascular disease patients in general, with a specific early clinical opportunity for end-stage renal disease (ESRD) patients on kidney dialysis, as cardiovascular disease causes most of their deaths and drug therapies have not improved their survival.
CardioDialysis is designed for use in hospitals and clinics worldwide that have dialysis machines, leveraging an existing global infrastructure of over 7,500 dialysis clinics in the U.S. and approximately 50,000 globally.
The global market for Lipoprotein Apheresis was estimated at $300 million in 2024 and is projected to reach $650 million in 2033, indicating growing demand despite distribution constraints, which supports the rationale for advancing CardioDialysis.
It addresses the unmet need in treating cardiovascular disease, especially in ESRD patients where drug therapies are ineffective, by offering a multi-target approach with broader accessibility through existing dialysis infrastructure.
In vitro studies have demonstrated CardioDialysis's ability to address a broad spectrum of inflammatory factors implicated in cardiovascular disease, and it is compared favorably to Lipoprotein Apheresis which has shown high efficacy in reducing MACE.
Sigyn Therapeutics, Inc., with inventor and CEO Jim Joyce authoring the note, is developing CardioDialysis as a dialysis-like therapy to treat cardiovascular disease and cancer.
Curated from NewMediaWire
